About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Cellgate Commences Phase II Clinical Trial of Anticancer Compound CGC-11047 for Prostate Cancer


Potent Anti-proliferative CGC-11047 Evaluated for PSA Improvements Prior to
Treatment with Chemotherapy

REDWOOD CITY, Calif., Nov. 1 /PRNewswire/ -- Cellgate Inc., a company
developing novel anti-proliferative drugs to combat cancers and other
disease, today announced the initiation of a Phase II clinical trial of its
lead compound, CGC-11047. CGC-11047 is a polyamine analog designed to halt
cell growth and induce apoptosis.
The Phase II clinical trial will enroll approximately 40 patients with
metastatic hormone refractory prostate cancer who have not yet received
prior chemotherapy. The primary endpoint for the study is efficacy based on
PSA (prostate specific antigen) response. Safety, tolerability and time to
progression will also be evaluated as part of the Phase II study. CGC-11047
will be administered intravenously as a single-agent by infusion once
weekly for three weeks over a four-week cycle at a dose of 200mg.
"I am pleased to be participating in this innovative prostate cancer
study designed to evaluate CGC-11074 in patients who are actively
monitoring elevated PSA levels but have not yet progressed to treatment
with chemotherapy," said George Wilding, M.D., Director of the University
of Wisconsin Comprehensive Cancer Center. "This patient population is a
large one, consisting of men with limited alternatives for managing their
disease. The potential to provide an effective means of controlling the
progression of their cancer without the toxicities associated with
traditional chemotherapies would represent an important improvement in
patient care."
"We are excited to be commencing Phase II clinical studies with our
lead compound, CGC-11047, a polyamine analog with anti-proliferative
properties," said Edward F. Schnipper, M.D., President and Chief Executive
Officer of Cellgate. "CGC-11047 has been very well-tolerated in Phase I
clinical trials and has demonstrated promising activity in patients with
advanced disease. Based on these initial results and CGC-11047's mechanism,
we feel this is an ideal agent for this patient population."
Polyamines are cell components considered essential for cell
proliferation and differentiation. Cellgate has developed polyamine analogs
that target proliferating cells. Cellgate's compounds are believed to work
by displacing polyamines from their natural binding sites and preventing
cell replication. In two separate Phase I clinical trials, a total of 20
patients (with a variety of advanced solid tumors) have been treated with
CGC-11047 to date. CGC-11047 has been well tolerated with no dose-limiting
toxicities reported. Preclinical in vitro studies have shown that CGC-11047
is cytotoxic to several standard tumor cell lines.
About Prostate Cancer
Prostate cancer is the second most common type of cancer found in
American men. The American Cancer Society estimates that there will be
about 234,460 new cases of prostate cancer in the United States in 2006.
Treatment for prostate cancer varies based on factors such as age, overall
health and the stage and grade of the cancer. Currently available
treatments include watchful waiting, surgery, radiation and hormone
therapy. Prostate cancer is the third leading cause of cancer death in men,
after lung cancer and colorectal cancer and approximately 27,350 men will
die of prostate cancer this year.
About Cellgate
Cellgate Inc. is a privately-held company advancing a portfolio of
anti- proliferative therapeutics with the potential to address a number of
diseases, including cancer, in which uncontrolled cell division is an
underlying cause. The company's lead products are advanced polyamine
analogs that act by selectively targeting proliferating cells and inducing
cell death to halt the progress of disease. Cellgate has two anti-cancer
polyamine analog compounds, CGC-11047 and CGC-11093, currently in Phase II
and Phase I clinical trials with leading investigators. Cellgate has also
established a portfolio of promising anti-proliferative leads, including a
novel compound with demonstrated preclinical activity in macular
degeneration. For more information about Cellgate, please visit
http://www.cellgate.com.

Whilst not in any way undermining the critical importance of cancer treatments, if it isn't specific to EIRX can I suggest an alternative thread is used for general info.

PH put a link to the information and explain why it is relevant and people can choose to look or not. Keep it simple and short!

That's a good idea ph, a link please as it is I don't read most off your long posts as I am well past middle age and so I can't spare the time.

Mr Turbot
PH Has got his own thread but he just likes to annoy us on here he gets a kick out of it, he also treats fellow investors with contempt and yes he will dump when he is ready and then deramp the answer is to squash him if you have had enough.

guys I post it as it is relevant, its a good idea to DYOR, I just give a bit of source for you to use as reference. if ya going to be lazy, why on earth do you trade

Driver, there is one important thing you have missed off your header

who are the major shareholders and how many shares do they have.

I think you will find the ex director is selling off his shares now he is retired

PH
Re "missed off your header"

I can't see it on your thread.

exactly noone has put the info up..

how about you do it

an awful lot of takeovers happening this week...

someone is certainly eating up our stock

potatohead

Are they lightly to confirm any milestone payments on there results day 11 Nov Approx?

Lots of 500000 going through @ 0.0032 showing as sell but they must be buys.

Marcel
They are buys just checked Barclays 500000 to buy at .32

why do you think share price has dropped?

marcel1970 because the hype has

700202
The hype may have dropped but the volume hasnt a few months ago you would have been lucky to have seen a couple of trades for the whole day, happy to hold at these levels till we get more news. If you believe in ERX top up on the dips.

DRIVER I believe and am holding 5 mil and will top up , but get fed up with idiots putting old or unconnected news hype on the site
could be massive news for cancer sufferers, without the crap

what crap, its all relevant, its all about cancer.. so your statement is contradictive 700202

I think some of it PH is that its old and they have seen it all before !!

actually none of it is old, it comes straight from google news

ya plonker